← Analyst Upside
AU · rank #9 · 2026-06-04
CORT
NASDAQ · $7.15B
verdict · CAUTION
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.478 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.89 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.177 |
| Analyst upside Consensus target $79.00 | +8.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +113.54% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $91.00 |
| Market cap | $7.15B |
The AI research card
Independent qualitative review of each pick before the order is placed.
Summary
Corcept Therapeutics Incorporated focuses on developing and commercializing therapies for cancer and metabolic disorders.
Rationale
The quant model indicates strong analyst upside potential with a high rating and significant momentum acceleration, suggesting positive sentiment.
Material risks
- 1Potential regulatory hurdles could impact product approvals and market access.
- 2Dependence on a limited number of products may expose the company to revenue volatility.
Verdict reasoning
two_stage score=+1/3 verdicts={'claude': 'CAUTION', 'openai': 'PROCEED', 'gemini': 'CAUTION'} brief=caller-supplied